中剂量阿糖胞苷治疗复发性急淋(ALL)近期疗效观察
CHINESE JOURNAL OF MEDICINE(2003)
Abstract
近十年来急性淋巴细胞性白血病(ALL)的初始安全缓解率显著提高,国内外报道在55%~85%[1],但成人急淋复发率高、生存期短,已成为目前治疗急淋的难点,如何提高难治性及复发性急淋的完全缓解率以延长患者的存活期仍为目前研究的重点.
MoreAI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined